Humanetics Corporation Receives Funding to Study New Drug for Idiopathic Pulmonary Fibrosis
The funding will support a series of studies with its new drug candidate, BIO 300.
- The funding will support a series of studies with its new drug candidate, BIO 300.
- The studies will focus on the ability of BIO 300 to attenuate progressive pulmonary fibrosis as a potential treatment for idiopathic pulmonary fibrosis (IPF).
- Notably, the drug has been shown to mitigate inflammation of the lungs (pneumonitis) and pulmonary fibrosis caused by radiation.
- Humanetics further expanded applications for the drug into cancer radiation therapy, COVID-19, and other inflammatory pulmonary diseases.